Specifically, one commenter suggested that CMS consider unpackaging their product, a contrast agent, and believed CMS's reasoning in the CY 2026 OPPS/ASC proposed rule for unpackaging and paying separately for diagnostic radiopharmaceuticals applies equally or even more to their product, since the cost of their product is over 500 times greater than the amount reported for the policy packaged drugs offset associated with the Level II Urology APC
About 6.5% of FDA-era trial participants developed hypothyroidism, which is why thyroid checks were built into the original prescribing pattern
That same stomach-slowing window is why oral birth control needs backup
Scientific Reports , 10
(PubMed) If AOD-9604 re-enters mainstream clinical availability through compliant channels, the most responsible use-case will likely be: carefully selected patients, realistic expectations, body composition focus, and as an adjunctnot a centerpiece
When your baseline is already depleted, normal stressors feel disproportionately heavy